Oramed Pharmaceuticals Inc.

DB:OJU1 Stock Report

Market Cap: €77.3m

Oramed Pharmaceuticals Management

Management criteria checks 2/4

Oramed Pharmaceuticals' CEO is Nadav Kidron, appointed in Mar 2006, has a tenure of 19.17 years. total yearly compensation is $2.10M, comprised of 25.7% salary and 74.3% bonuses, including company stock and options. directly owns 4.74% of the company’s shares, worth €3.66M. The average tenure of the management team and the board of directors is 12.4 years and 8.7 years respectively.

Key information

Nadav Kidron

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage25.75%
CEO tenure19.2yrs
CEO ownership4.7%
Management average tenure12.4yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nadav Kidron's remuneration changed compared to Oramed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$28m

Dec 31 2024US$2mUS$540k

-US$19m

Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

US$21m

Mar 31 2024n/an/a

US$10m

Dec 31 2023US$2mUS$463k

US$6m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$7mUS$491k

-US$37m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021n/an/a

-US$35m

Nov 30 2021n/an/a

-US$25m

Aug 31 2021US$4mUS$466k

-US$22m

May 31 2021n/an/a

-US$18m

Feb 28 2021n/an/a

-US$15m

Dec 31 2020n/an/a

-US$22m

Nov 30 2020n/an/a

-US$15m

Aug 31 2020US$2mUS$439k

-US$12m

May 31 2020n/an/a

-US$11m

Feb 29 2020n/an/a

-US$13m

Nov 30 2019n/an/a

-US$13m

Aug 31 2019US$2mUS$419k

-US$14m

May 31 2019n/an/a

-US$15m

Feb 28 2019n/an/a

-US$15m

Nov 30 2018n/an/a

-US$14m

Aug 31 2018US$2mUS$436k

-US$13m

Compensation vs Market: Nadav's total compensation ($USD2.10M) is above average for companies of similar size in the German market ($USD493.82K).

Compensation vs Earnings: Nadav's compensation has increased whilst the company is unprofitable.

CEO

Nadav Kidron (50 yo)

19.2yrs
Tenure
US$2,097,689
Compensation

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...

Leadership Team

NamePositionTenureCompensationOwnership
Nadav Kidron
President19.2yrsUS$2.10m4.74%
€ 3.7m
Avraham Gabay
CFO, Treasurer & Secretaryless than a yearUS$753.15k0.30%
€ 230.3k
Miriam Kidron
Chief Scientific Officer & Director19.2yrsUS$1.53m1.77%
€ 1.4m
Joshua Hexter
Chief Operating & Business Officer5.7yrsUS$1.28m1.13%
€ 876.4k
12.4yrs
Average Tenure
52yo
Average Age

Experienced Management: OJU1's management team is seasoned and experienced (12.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nadav Kidron
President19.2yrsUS$2.10m4.74%
€ 3.7m
Miriam Kidron
Chief Scientific Officer & Director19.2yrsUS$1.53m1.77%
€ 1.4m
Jay Skyler
Member of Scientific Advisory Board5.3yrsno datano data
Eleuterio Ferrannini
Member of Scientific Advisory Board18.3yrsno datano data
Harold Jacob
Member of Scientific Advisory Board8.5yrsUS$20.00kno data
Avram Hershko
Member of Scientific Advisory Board16.8yrsno datano data
G. Alexander Fleming
Member of Scientific Advisory Board5.4yrsno datano data
Leonard Sank
Independent Director17.6yrsUS$135.10k0.15%
€ 118.3k
Roy Eldor
Member of the Scientific Advisory Board8.8yrsno datano data
Anne Peters
Member of Scientific Advisory Board2.9yrsno datano data
Arie Mayer
Independent Director5.4yrsUS$135.95k0.15%
€ 114.8k
Julio Rosenstock
Member of Scientific Advisory Board5.3yrsno datano data
8.7yrs
Average Tenure
70yo
Average Age

Experienced Board: OJU1's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 08:57
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oramed Pharmaceuticals Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Christopher JamesFBR Capital Markets & Co.